Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2021

Primary Completion Date

February 28, 2024

Study Completion Date

October 23, 2027

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (118)

1200

Local Institution, Brussels

2000

Local Institution, Odense C

2060

Local Institution, North Sydney

2145

Local Institution, Westmead

2610

Local Institution, Wilrijk

2730

Local Institution, Herlev

3000

Local Institution, Melbourne

3004

Local Institution, Melbourne

3100

Local Institution, Sankt Pölten

3350

Local Institution, Ballarat

4120

Local Institution, Greenslopes

Local Institution, Woolloongabba

5000

Local Institution, Adelaide

5020

Local Institution, Salzburg

6009

Local Institution, Nedlands

6018

Local Institution, Doubleview

6020

Local Institution, Innsbruck

6200

Local Institution, Nice

7000

Local Institution, Hobart

8035

Local Institution, Haddon Heights

8200

Local Institution, Aarhus

9000

Local Institution, Ghent

10117

Local Institution, Berlin

13385

Local Institution, Marseille

15706

Local Institution, Santiago de Compostela

21079

Local Institution, Dijon

21401

Local Institution, Annapolis

22908

Local Institution, Charlottesville

23538

Local Institution, Lübeck

24105

Local Institution, Kiel

24127

Local Institution, Bergamo

27100

Local Institution, Pavia

28007

Local Institution, Madrid

28100

Local Institution, Novara

29010

Local Institution, Málaga

30060

Local Institution, Marietta

30322

Local Institution, Atlanta

30342

Local Institution, Atlanta

30625

Local Institution, Hanover

31059

Local Institution, Toulouse

33011

Local Institution, Oviedo

33075

Local Institution, Bordeaux

33612

Local Institution, Tampa

35000

Local Institution, Rennes

35128

Local Institution, Padua

39401

Local Institution, Hattiesburg

41009

Local Institution, Seville

42270

Local Institution, Sr Priest En Jarez

44093

Local Institution, Nantes

44195

Local Institution, Cleveland

45122

Local Institution, Essen

47014

Local Institution, Meldola

55131

Local Institution, Mainz

55407

Local Institution, Minneapolis

55455

Local Institution, Minneapolis

59000

Local Institution, Lille

63110

Local Institution, St Louis

69120

Local Institution, Heidelberg

69495

Local Institution, Pierre-Bénite

72076

Local Institution, Tübingen

75010

Local Institution, Paris

77030

Local Institution, Houston

80045

Local Institution, Aurora

80131

Local Institution, Napoli

84112

Local Institution, Salt Lake City

85234

Local Institution, Gilbert

85724

Local Institution, Tucson

91054

Local Institution, Erlangen

93053

Local Institution, Regensburg

94158

Local Institution, San Francisco

94800

Local Institution, Villejuif

97080

Local Institution, Würzburg

97239

Local Institution, Portland

98109

Local Institution, Seattle

197758

Local Institution, Saint Petersburg

198255

Local Institution, Saint Petersburg

350000

Local Institution, Krasnodar

390011

Local Institution, Ryazan

60135237

Local Institution, Fortaleza

02114

Local Institution, Boston

02215

Local Institution, Boston

07960

Local Institution, Morristown

08901

Local Institution, New Brunswick

803 6

Local Institution, Graz

A-1090

Local Institution, Vienna

70200-730

Local Institution, Brasília

80530-010

Local Institution, Curitiba

90035-903

Local Institution, Porto Alegre

90050-170

Local Institution, Porto Alegre

91350-200

Local Institution, Porto Alegre

88034-000

Local Institution, Florianópolis

15092-415

Local Institution, São José do Rio Preto

20220-410

Local Institution, Rio de Janeiro

01246-000

Local Institution, São Paulo

05308-020

Local Institution, São Paulo

1066CX

Local Institution, Amsterdam

1081 HV

Local Institution, Amsterdam

4818 CK

Local Institution, Breda

6162bg

Local Institution, Geleen

2333 ZA

Local Institution, Leiden

3075 EA

Local Institution, Rotterdam

3584CX

Local Institution, Utrecht

31-115

Local Institution, Krakow

02-781

Local Institution, Warsaw

53-413

Local Institution, Wroclaw

08036

Local Institution, Barcelona

352 34

Local Institution, Vaxjo

CH - 8091

Local Institution, Zurich

CB2 0QQ

Local Institution, Cambridge

G12 0YN

Local Institution, Glasgow

GU2 7XX

Local Institution, Guildford

LS9 7TF

Local Institution, Leeds

SE1 9RT

Local Institution, London

SW3 6JJ

Local Institution, London

M20 4BX

Local Institution, Manchester

HA6 2RN

Local Institution, Northwood

OX3 7LE

Local Institution, Oxford

SM2 5PT

Local Institution, Sutton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04495010 - Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | Biotech Hunter | Biotech Hunter